Innovations in CAR T-Cell Therapies for Myeloma

This chapter explores the intricacies of CAR T-cell therapies, specifically Idacel and Siltacel, in treating multiple myeloma. It highlights key differences in efficacy, binding mechanisms, and response rates based on trial data, while addressing ongoing research and the risks of toxicity. Additionally, the chapter emphasizes the importance of therapy sequencing and its impact on patient outcomes, using real case studies to illustrate these complexities.